The new tailored agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase inhibitors, are able to inactivate specific molecular alterations that occur in specific oncogenes, which cause cancer cell survival strictly dependent on such aberrant genes, as explained by the “oncogene addiction theory” (1). The gene discussed is EGFR; the disease is cancer.